Pathways to Prevention (P2P)

Workshop Program

Workshop Agenda

 

Day 1 – October 30, 2018
8:30 a.m. to 5:30 p.m. Eastern Time

See Day 2: October 31, 2018 »

 

Introductory Session

8:30 a.m.

Opening Remarks

Stephen I. Katz, M.D., Ph.D.
Director
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health


8:40 a.m.

Welcome and Charge to the Panel

David M. Murray, Ph.D.
Associate Director of Disease Prevention
Director, Office of Disease Prevention
Division of Program Coordination, Planning, and Strategic Initiatives
Office of the Director
National Institutes of Health


8:50 a.m.

Workshop Overview and Panel Activities

Albert Siu, M.D., M.S.P.H.
Workshop and Panel Chair
Director of Mount Sinai at Home
Professor and Chairman Emeritus, The Brookdale Department of Geriatrics and Palliative Medicine
Icahn School of Medicine at Mount Sinai


 

Overview of Osteoporotic Fractures and Drugs to Prevent Them

9:00 a.m.

Osteoporotic Fracture Prevention in the United States

Elizabeth Shane, M.D.
Professor of Medicine
Department of Medicine
Columbia University Medical Center


9:20 a.m.

FDA-Approved Pharmacologic Options for Fracture Prevention

Sundeep Khosla, M.D.
Professor of Medicine
Department of Endocrinology and Kogod Center on Aging
Mayo Clinic


9:35 a.m.

Overview of NIH Portfolio on Osteoporotic Fracture Prevention

Faye Chen, Ph.D.
Program Director
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health


9:45 a.m.

The Translational Pipeline: A Regulatory Perspective

Theresa Kehoe, M.D.
Lead Medical Officer
Center for Drug Evaluation and Research
U.S. Food and Drug Administration


10:00 a.m.

Break


 

Key Question 1:

What are the benefits and risks (including major adverse events) of osteoporotic drugs with short-term use (from first use up to 3-5 years of treatment)? What factors influence outcomes?

10:10 a.m.

Evidence-based Practice Center Presentation – Short-Term Treatments to Prevent Osteoporotic Fractures

Meera Viswanathan, Ph.D.
Director, RTI-UNC Evidence-based Practice Center


10:30 a.m.

Short-Term Drug Therapy for Osteoporotic Fracture Prevention – Balancing Benefits and Risks

Clifford J. Rosen, M.D.
Department of Clinical and Translational Research
Senior Scientist, Maine Medical Center Research Institute


 

Key Question 4, Part 1:

What patient and clinician factors impact the use of and adherence to osteoporotic drugs?

10:50 a.m.

Short-Term Drug Therapy for Osteoporotic Fracture Prevention – Prescribing in the Primary Care Setting

James M. Gill, M.D., M.P.H.
President and Principal Investigator
Delaware Valley Outcomes Research


11:10 a.m.

Short-Term Drug Therapy for Osteoporotic Fracture Prevention – Acceptance by Patients

Stuart L. Silverman, M.D.
Clinical Professor of Medicine
Cedars-Sinai Medical Center and UCLA School of Medicine
Osteoporosis Medical Center


11:30 a.m.

Drug Therapy for Osteoporotic Fracture Prevention – Improving Adherence

Deborah T. Gold, Ph.D.
Professor of Medical Sociology
Departments of Psychiatry and Behavioral Sciences, Sociology, and Psychology and Neuroscience
Duke University Medical Center


11:50 a.m.

Discussion

Moderated by
Albert Siu, M.D., M.S.P.H.


12:30 p.m.

Lunch


1:30 p.m.

Patients’ Perspectives

Moderated by
Carrie Klabunde, Ph.D.
Senior Advisor for Disease Prevention, P2P Program Team Lead
Division of Program Coordination, Planning and Strategic Initiatives
Office of Disease Prevention
National Institutes of Health

Patient Representatives:

Gerry O’Connor

Barbara Hannah Grufferman

Nancy Ostrove

 


Key Question 2:

What are the benefits and risks of osteoporotic drugs over the longer term (for treatment periods > 3 years)? What factors influence the outcomes?

1:50 p.m.

Evidence-based Practice Center Presentation – Long-Term Osteoporosis Drug Therapy: Benefits and Effect Modifiers of Benefits

Howard Fink, M.D., M.P.H.
Principal Investigator, Minnesota Evidence-based Practice Center
Minneapolis Veterans Affairs Health Care System


2:10 p.m.

Impact of Long-Term Osteoporosis Treatment and Drug Holidays on Fracture Risk: Evidence from Observational Studies

Dennis Black, Ph.D.
Professor
Department of Epidemiology and Biostatistics
University of California, San Francisco
2:30 p.m.

Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators for Prevention and Treatment of Osteoporosis: The Balance of Benefits and Risks

Rebecca D. Jackson, M.D.
Professor 
Division of Endocrinology, Diabetes and Metabolism
The Ohio State University, Wexner Medical Center


2:50 p.m.

Fracture Prevention Strategies Beyond Antiresorptives: Anabolics and Combination Therapies

Felicia Cosman, M.D.
Professor of Medicine
Department of Medicine
Columbia University College of Physicians and Surgeons


3:10 p.m.

Break


3:20 p.m.

Evidence-based Practice Center Presentation – Long-term Drug Therapy: Harms and Effect Modifiers of Harms

Howard Fink, M.D., M.P.H.
Principal Investigator, Minnesota Evidence-based Practice Center
Minneapolis Veterans Affairs Health Care System


3:40 p.m.

Rare but Serious Adverse Events Associated with Long-Term Antiresorptive Therapy – Who’s at Risk? How to Manage?

Atypical Femoral Fractures (AFF)

Robert A. Adler, M.D.
Chief, Department of Endocrinology
McGuire Veterans Affairs Medical Center
Professor of Medicine, Virginia Commonwealth University School of Medicine


4:00 p.m.
 
Osteonecrosis of the Jaw (ONJ)

Tara Aghaloo, D.D.S., M.D., Ph.D.
Professor and Assistant Dean for Clinical Research
Department of Oral and Maxillofacial Surgery
University of California, Los Angeles School of Dentistry


4:15 p.m.

Other Side Effects of Antiresorptive Therapies

Juliet Compston, M.D.
Professor Emeritus of Bone Medicine
Department of Medicine
University of Cambridge School of Clinical Medicine, UK


4:35 p.m.

Discussion

Moderated by
Albert Siu, M.D., M.S.P.H.


5:25 p.m.

Wrap-up and Preview of Day Two

Albert Siu, M.D., M.S.P.H.


5:30 p.m.

Adjourn


Attendees will be responsible for meals and/or light refreshments on their own, at their own cost. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.

See Day 2: October 31, 2018 »

Last updated on April 17, 2020